Prevention of primary non-function of islet xenografts in autoimmune diabetic NOD mice by anti-inflammatory agents

Diabetologia

Volumn 46, Issue 8, 2003, Pages 1115-1123

  Gysemans, C ^a   Stoffels, K ^a   Giulietti, A ^a   Overbergh, L ^a   Waer, M ^b   Lannoo, M ^c   Feige, U ^d   Mathieu, C ^a  

^a LEGENDO   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d AMGEN INC   (United States)

Author keywords

Inflammatory cytokines; Islets; Nitric oxide; NOD mice; Primary non function

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CHEMOKINE; CYCLOOXYGENASE 2; INTERLEUKIN 1; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; NITRITE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; ROFECOXIB; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GRAFT FAILURE; GRAFT SURVIVAL; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RAT; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SURVIVAL TIME; XENOGRAFT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CYCLOOXYGENASE INHIBITORS; DIABETES MELLITUS, TYPE 1; GRAFT SURVIVAL; ISLETS OF LANGERHANS TRANSPLANTATION; LACTONES; MICE; MICE, INBRED NOD; SULFONES; TRANSPLANTATION, HETEROLOGOUS;

EID: 0041376742     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-003-1154-0     Document Type: Article

References (48)

1. Bretzel RG, Hering BJ, Federlin KF (1995) Islet cell transplantation in diabetes mellitus - from bench to bedside. Exp Clin Endocrinol Diabetes 103 [Suppl 2]:143-159
2. Samuel T, Cockwell P (2002) Islet cell transplantation. J R Soc Med 95 1:31-33
3. Shapiro AM, Lakey JR, Ryan EA et al. (2000) Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230-238
4. Ryan EA, Lakey JR, Rajotte RV et al. (2001) Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 50:710-719
5. Pipeleers D, Keymeulen B, Chatenoud L et al. (2002) A view on beta cell transplantation in diabetes. Ann NY Acad Sci 958:69-76
6. Kendall WF Jr, Collins BH, Opara EC (2001) Islet cell transplantation for the treatment of diabetes mellitus. Expert Opin Biol Ther 1:109-119
7. Wallgren AC, Karlsson-Parra A, Korsgren O (1995) The main infiltrating cell in xenograft rejection is a CD4+ macrophage and not a T lymphocyte. Transplantation 60:594-601
8. Yi S, Feng X, Hawthorne WJ, Patel AT, Walters SN, O'Connell PJ (2002) CD4+ T cells initiate pancreatic islet xenograft rejection via an interferon-gamma-dependent recruitment of macrophages and natural killer cells. Transplantation 73:437-446
9. Brauker J, Martinson LA, Young SK, Johnson RC (1996) Local inflammatory response around diffusion chambers containing xenografts. Nonspecific destruction of tissues and decreased local vascularization. Transplantation 61:1671-1677
10. Deng S, Ketchum RJ, Kucher T, Weber M, Naji A, Brayman KL (1997) Primary non-function of islet xenografts in rat recipients results from non-T-cell mediated immune responses. Transplant Proc 29:1726-1727
11. Gysemans CA, Waer M, Valckx D et al. (2000) Early graft failure of xenogenic islets in NOD mice is accompanied by high levels of IL-1 and low levels of TGF-β mRNA in the grafts. Diabetes 49:1992-1997
12. Alleva DG, Pavlovich RP, Grant C, Kaser SB, Beller DI (2000) Aberrant macrophage cytokine production is a conserved feature among autoimmune-prone mouse strains. Elevated interleukin (IL)-12 and an imbalance in tumor necrosis factor-α and IL-10 define a unique cytokine profile in macrophages from young NOD mice. Diabetes 49:1106-1115
13. Charre S, Rosmalen JG, Pelegri C et al. (2002) Abnormalities in dendritic cell and macrophage accumulation in the pancreas of nonobese diabetic (NOD) mice during the early neonatal period. Histol Histopathol 17:393-401
14. O'Brien BA, Huang Y, Geng X, Dutz JP, Finegood DT (2002) Phagocytosis of apoptotic cells by macrophages from NOD mice is reduced. Diabetes 51:2481-2488
15. Jansen A, Hagen M van, Drexhage HA (1995) Defective maturation and function of antigen-presenting cells in type 1 diabetes. Lancet 345:491-492
16. Plesner A, Greenbaum CJ, Gaur LK, Ernst RK, Lernmark A (2002) Macrophages from high-risk HLA-DQB1*0201/*0302 type 1 diabetes mellitus patients are hypersensitive to lipopolysaccharide stimulation. Scand J Immunol 56:522-529
17. Vial T, Choquet-Kastylevsky G, Descotes J (2002) Adverse effects of immunotherapeutics involving the immune system. Toxicology 174:3-11
18. Gysemans C, Waer M, Laureys J, Bouillon R, Mathieu C (2001) A combination of KH1060, a vitamin D(3) analogue, and cyclosporin prevents early graft failure and prolongs graft survival of xenogeneic islets in nonobese diabetic mice. Transplant Proc 33:2365
19. Gysemans C, Waer M, Laureys J, Bouillon R, Mathieu C (2001) Leflunomide and its analogue X920715 synergize with cyclosporin A in preventing early graft failure and delaying graft rejection of xenogeneic islets in nonobese diabetic mice. Transplant Proc 33:2094-2095
20. Pozzilli P, Signore A, Williams AJ, Beales PE (1993) NOD mouse colonies around the world: recent facts and figures. Immunol Today 14:193-196
21. Overbergh L, Valckx D, Waer M, Mathieu C (1999) Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 11:305-312
22. Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C (2001) An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 25:386-401
23. Cardozo AK, Proost P, Gysemans C, Chen MC, Mathieu C, Eizirik D (2002) IL-1β and IFN-γ induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice. Diabetologia 46:255-266
24. Falcon M, Sarvetnick N (1999) The effect of local production of cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Clin Immunol 90:2-9
25. Mathis D, Vence L, Benoist C (2001) β-cell death during progression to diabetes. Nature 414:792-798
26. Eizirik DL, Mandrup-Poulsen T (2001) A choice of death - the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 44:2115-2133
27. Serreze DV (1993) Autoimmune diabetes results from genetic defects manifest by antigen presenting cells. FASEB J 7:1092-1096
28. Liu J, Beller D (2002) Aberrant production of IL-12 by macrophages from several autoimmune-prone mouse strains is characterized by intrinsic and unique patterns of NF-kappa B expression and binding to the IL-12 p40 promoter. J Immunol 169:581-586
29. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC (2002) Post-transplantation diabetes: a systematic review of the literature. Diabetes Care 25:583-592
30. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232-235
31. Gautam SC, Pindolia KR, Noth CJ, Janakiraman N, Xu YX, Chapman RA (1995) Chemokine gene expression in bone marrow stromal cells: down-regulation with sodium salicylate. Blood 86:2541-2550
32. Sakurada S, Kato T, Okamoto T (1996) Induction of cytokines and ICAM-1 by pro-inflammatory cytokines in primary rheumatoid synovial fibroblasts and inhibition by N-acetyl-L-cysteine and aspirin. Int Immunol 8:1483-1493
33. Shackelford RE, Alford PB, Xue Y, Thai SF, Adams DO, Pizzo S (1997) Aspirin inhibits tumor necrosis factor-alpha gene expression in murine tissue macrophages. Mol Pharmacol 52:421-429
34. Shi X, Ding M, Dong Z et al. (1999) Antioxidant properties of aspirin: characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF-kappaB activation, and TNF-alpha production. Mol Cell Biochem 199:93-102
35. Weissmann G (1991) Aspirin. Sci Am 264:84-90
36. Tegeder I, Pfeilschifter J, Geisslinger G (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15:2057-2072
37. Chen MC, Proost P, Gysemans C, Mathieu C, Eizirik DL (2001) Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and IL-1β exposed human and rat islet cells. Diabetologia 44:325-332
38. Hillson JL, Furst DE (2000) Rofecoxib. Expert Opin Pharmacother 1:1053-1066
39. Atkinson HG (2002) COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs. Health News 8:5
40. Clark DA, Coker R (1998) Transforming growth factor-beta (TGF-beta). Int J Biochem Cell Biol 30:293-298
41. Lin JY, Seguin R, Keller K, Chadee K (1995) Transforming growth factor-beta 1 primes macrophages for enhanced expression of the nitric oxide synthase gene for nitric oxide-dependent cytotoxicity against Entamoeba histolytica. Immunology 85:400-407
42. Prud'homme GJ, Lawson BR, Theofilopoulos AN (2001) Anticytokine gene therapy of autoimmune diseases. Expert Opin Biol Ther 1:359-373
43. Mandrup-Poulsen T (1996) The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 39:1005-1029
44. Granowitz EV, Vannier E, Poutsiaka DD, Dinarello CA (1992) Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: II. IL-1 receptor antagonist inhibits lipopolysaccharide-induced cytokine synthesis by human monocytes. Blood 79:2364-2369
45. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB (1996) Anti-cytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 39:797-809
46. Eiririk DL, Flodström M, Karlsen AE, Welsh N (1996) The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells. Diabetologia 39:875-890
47. Hammond RA, Hannon R, Frean SP, Armstrong SJ, Flower RJ, Bryant C (1999) Endotoxin induction of nitric oxide synthase and cyclooxygenase-2 in equine alveolar macrophages. Am J Vet Res 60:426-431
48. Gallo O, Fabbroni V, Sardi I, Magnelli L, Boddi V, Franchi A (2002) Correlation between nitric oxide and cyclooxygenase-2 pathways in head and neck squamous cell carcinomas. Biochem Biophys Res Commun 299:517-524